# Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes

Study · id `cardio:ct-nct04943692` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04943692](<https://clinicaltrials.gov/study/NCT04943692>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04943692

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 500 participants.

## Technical summary

Registry record NCT04943692. Randomized; double masking; primary purpose treatment. Start 2021-08 (anticipated); primary completion 2021-08 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 500 participants (planned count; ClinicalTrials.gov record NCT04943692, source copy `cardio:ctgov-nct04943692-2021-06-29`, retrieved 2026-10-26)
- Planned start: 2021-08 (anticipated) (ClinicalTrials.gov record NCT04943692, source copy `cardio:ctgov-nct04943692-2021-06-29`, retrieved 2026-10-26)
- Primary completion: 2021-08 (anticipated) (ClinicalTrials.gov record NCT04943692, source copy `cardio:ctgov-nct04943692-2021-06-29`, retrieved 2026-10-26)
- Completion: 2021-08 (anticipated) (ClinicalTrials.gov record NCT04943692, source copy `cardio:ctgov-nct04943692-2021-06-29`, retrieved 2026-10-26)
- Countries: Mexico (ClinicalTrials.gov record NCT04943692, source copy `cardio:ctgov-nct04943692-2021-06-29`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "SUSPENDED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04943692-2021-06-29`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes
- Acronym: COMETII
- Condition: Type 2 Diabetes
- Intervention (Drug): Metformin glycinate
- Intervention (Drug): Metformin Hydrochloride
- Lead sponsor: Laboratorios Silanes S.A. de C.V.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Laboratorios Silanes S.A. de C.V. (`cardio:org-laboratorios-silanes-s-a-de-c-v`)

## Provenance

Content hash: e5df0ca0518270b3df3c0b7ae5bf14d8ef93328fed8f2abc653374e58b8fea64
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
